Equity Overview
Price & Market Data
Price: $1.94
Daily Change: $0.00 / 0.00%
Daily Range: $1.68 - $2.04
Market Cap: $187,476,176
Daily Volume: 1,605,510
Performance Metrics
1 Week: 1.57%
1 Month: 7.78%
3 Months: 22.01%
6 Months: -14.16%
1 Year: 125.3%
YTD: 22.01%
Company Details
Employees: 97
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.